Skip to content
The Policy VaultThe Policy Vault

Ilaris (canakinumab) — Highmark

Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS)

Initial criteria

  • age ≥ 4 years
  • diagnosis of Familial Cold Autoinflammatory Syndrome (FCAS) OR Muckle-Wells Syndrome (MWS)
  • prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist

Reauthorization criteria

  • member is tolerating therapy AND has experienced disease improvement OR delayed disease progression